Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
Delivers Global First With Ranibizumab Biosimilar Launch Through Partner Biogen
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.
You may also be interested in...
Rumors of another major biosimilars deal are spreading after Korean media reported that Samsung Bioepis could be considering a bid for Biogen’s biosimilars business.
Xbrane has announced the formal acceptance by the US FDA of its re-filed ranibizumab biosimilar, developed in collaboration with Stada and licensed in North America to Bausch + Lomb.
Biogen revealed that a formal process is now underway to “evaluate strategic options” for its biosimilars business, pointing to a potential transfer of the unit to a new owner.